IPCA Laboratories Ltd

Ipca Laboratories has appointed Saidutta Nanda as President ' Human Resources of the company with effect from 3 March 2025.Powered by Capital Market - Live

Ipca Laboratories Ltd is down for a fifth straight session today. The stock is quoting at Rs 1356.5, down 0.89% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.84% on the day, quoting at 22131.1. The Sensex is at 73233.39, down 1.85%.Ipca Laboratories Ltd has lost around 6.01% in last one month.Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has eased around 6.27% in last one month and is currently quoting at 20201.25, down 1.81% on the day. The volume in the stock stood at 1.28 lakh shares today, compared to the daily average of 4.91 lakh shares in last one month.The PE of the stock is 41.97 based on TTM earnings ending December 24.Powered by Capital Market - Live

Net profit of Ipca Laboratories rose 37.95% to Rs 248.14 crore in the quarter ended December 2024 as against Rs 179.88 crore during the previous quarter ended December 2023. Sales rose 9.38% to Rs 2245.37 crore in the quarter ended December 2024 as against Rs 2052.85 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2245.372052.85 9 OPM %20.6216.12 - PBDT466.38319.93 46 PBT367.92220.43 67 NP248.14179.88 38 Powered by Capital Market - Live

Revenue from operations jumped 10.34% YoY to Rs 1,662.68 crore in the quarter ended 31st December 2024. Profit before tax (PBT) increased 77.63% to Rs 355.52 crore in Q3 FY25 as compared with Rs 200.15 crore in Q3 FY24. EBITDA stood at Rs 446.07 crore in Q3 FY25, registering the growth of 35% as compared with Rs 330.52 crore in Q3 FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) stood at 19.87% in Q3 FY25 as against at 16.10% in Q3 FY24. During the quarter, total formulations were at Rs 1,335.32 crore, up 10% YoY. Domestic business stood at Rs 877.17 crore (up 13% YoY). Total revenue from active pharmaceutical ingredient (API) stood at Rs 317.92 crore (up 12% YoY). revenue from domestic business stood at Rs 95.16 crore (up 22%) while exports were at Rs 222.76 crore (up 7%) during the period under review. Ipca Laboratories is an Indian multinational pharmaceutical company. It produces theobromine, acetylthiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally.Powered by Capital Market - Live

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live

Ipca Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1703.45, up 0.49% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 23759.900390625. The Sensex is at 78574.27, up 0.56%. Ipca Laboratories Ltd has gained around 11.12% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 4.35% in last one month and is currently quoting at 23412.25, up 0.06% on the day. The volume in the stock stood at 4.6 lakh shares today, compared to the daily average of 6.54 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1701, up 0.55% on the day. Ipca Laboratories Ltd is up 53% in last one year as compared to a 9.67% jump in NIFTY and a 35.62% jump in the Nifty Pharma index.The PE of the stock is 61.59 based on TTM earnings ending September 24.Powered by Capital Market - Live

Ipca Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 1656.9, up 1.49% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 23803.900390625. The Sensex is at 78735.73, up 0.05%. Ipca Laboratories Ltd has added around 8.08% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 3.31% in last one month and is currently quoting at 23008.35, up 0.8% on the day. The volume in the stock stood at 5.8 lakh shares today, compared to the daily average of 6.35 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1662.5, up 1.15% on the day. Ipca Laboratories Ltd is up 48.02% in last one year as compared to a 9.48% gain in NIFTY and a 37.57% gain in the Nifty Pharma index.The PE of the stock is 59.29 based on TTM earnings ending September 24.Powered by Capital Market - Live

Ipca Laboratories has received necessary approval for voluntary closure of its wholly owned subsidiary Ipca Pharmaceuticals SA de CV, Mexico. This wholly owned subsidiary incorporated in Mexico was not doing any business for the past several years. Voluntary closure of this wholly owned subsidiary will not have any impact on Company's business or financials.Powered by Capital Market - Live

Ipca Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 1591.25, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.25% on the day, quoting at 23745.85. The Sensex is at 78340.19, up 1.29%. Ipca Laboratories Ltd has slipped around 1.43% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has slipped around 5.27% in last one month and is currently quoting at 21544.15, up 1.67% on the day. The volume in the stock stood at 2.47 lakh shares today, compared to the daily average of 3.37 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1593.75, up 1.8% on the day. Ipca Laboratories Ltd is up 50.01% in last one year as compared to a 20.57% spurt in NIFTY and a 38.57% spurt in the Nifty Pharma index.The PE of the stock is 56.98 based on TTM earnings ending September 24.Powered by Capital Market - Live

Ipca Laboratories has fixed 27 November 2024 as record date for interim dividend for FY 2024-25. Powered by Capital Market - Live